What Are Aromatase Inhibitors and How Do They Block Estrogen in Men? | What Trials Show

Anastrozole, letrozole, and exemestane appear often in men’s health discussions despite no regulator approving them for male use. Understanding them means separating the enzyme they target, the hormone shifts that follow, and their off-label status.

Aromatase is the enzyme that makes estrogen. In men, the testes and adrenal glands produce testosterone, and aromatase converts some of it into estradiol, the main estrogen in men. Block the enzyme and estradiol falls. Because the pituitary reads falling estradiol as a cue to push harder, luteinizing hormone and follicle-stimulating hormone can climb, and the testes answer with more testosterone.

Aromatase Inhibitors And Estrogen In Men: What The Enzyme Does

Aromatase sits in fat tissue, the testes, the brain, and bone; in men, the largest share of testosterone-to-estradiol conversion happens in body fat. An aromatase inhibitor binds this enzyme and shuts down that conversion, so circulating estradiol drops.

Third-generation drugs dominate the literature. Anastrozole and letrozole are non-steroidal compounds that bind the enzyme reversibly; exemestane is steroidal and inactivates aromatase permanently, hence “suicide inhibitor.” All three lower estrogen; the difference for men is how complete and long-lasting the suppression is.

Aromatase inhibitors do not block estrogen receptors directly. They cut production at the source, unlike tamoxifen, which leaves estrogen circulating but occupies its docking sites.

Do Aromatase Inhibitors Raise Testosterone In Men?

Yes — testosterone often rises, but modestly and second-hand, through the pituitary rather than direct testicular action. When estradiol drops, the brain’s feedback brake on gonadotropin release loosens, LH and FSH rise, and the testes get a stronger signal to produce testosterone.

A pharmacokinetic study of exemestane in healthy men found that pattern: estradiol suppressed, testosterone increased. Anastrozole and letrozole show the same direction of effect in clinical work with adult men; the size of change varies, with men starting low seeing more movement than those already in the normal range.

Estrogen is not a waste product in male biology. Estradiol supports bone density, libido, mood, and joint health. Push it down too far and one hormone problem replaces another. A National Library of Medicine review of aromatase inhibitors lays out that pharmacology and the off-label status in men, and is blunt: long-term effectiveness and safety are not established.

Studied Uses In Men — And What Is Not Approved

Everything below is off-label — studied in small trials or reported case by case.

• Boys with pubertal delay or idiopathic short stature: studied to slow epiphyseal maturation and possibly add adult height, with long-term safety uncertain.
• Obesity-related hypogonadotropic hypogonadism: studied to lift gonadotropins in men whose extra fat drives aromatase activity up.
• Gynecomastia: studied as an alternative to surgery in select cases.
• Male subfertility: studied, with no approved protocol.

Two mistakes recur. The first is treating an aromatase inhibitor as a routine add-on to testosterone therapy; the literature calls that off-label and outside standard practice. The second is chasing a low estradiol number. Estrogen does real work in men, and excessive suppression can cost bone and joints. Over-the-counter “estrogen blockers” are a different category — supplements, not prescription enzyme inhibitors — and readers weighing those formulas can browse our tested roundup of estrogen blocker options for men.

If considering these drugs, get baseline testosterone, estradiol, LH, and FSH measured, work with a physician who reads those numbers in context, then recheck rather than guess. Dosage standards for men are not established, so anyone quoting a firm protocol is working from anecdote.